Checkpoint blockade immunotherapy has achieved durable responses in several solid tumor types by reinvigorating the anti-tumor function of T cells. However, many patients have shown limited responses and successful checkpoint blockade in solid tumors has exhibited little benefit in blood cancers, highlighting the significant importance of uncovering the unknown alternative immune-suppressive mechanism in hematologic malignancies. TIM-3 was originally identified as an inhibitory checkpoint receptor expressed on IFN\u03b3-producing T cells in Dr. Kuchroo\u2019s lab. More recently, they have reported that TIM-3 is also expressed on dendritic cells (DCs), where it regulates inflammasome activation and tumor growth. Moreover, TIM-3 has been observed to specifically express on leukemic stem cells in blood cancers, especially myeloid-lineage leukemia. Importantly, anti-Tim-3 antibody (MBG453, Sabatolimab) blockade has shown promising response rates in acute myeloid leukemia\/myelodysplastic syndrome patients. As the dysfunction of immune checkpoint regulation is a major impediment to effective cancer immunotherapy, investigating the mechanism of these inhibitory checkpoint receptors in blood cancers is critical for the development of successful immune-based therapies. Targeting the unexplored TIM-3-driven pathways in myeloid cells may not only have the potential to inhibit the intrinsic unlimited proliferation of leukemic cells, but may also boost the extrinsic anti-tumor immune response, emphasizing a \u201cone stone kills two birds\u201d effect. Furthermore, mechanistically characterizing the immune-regulating role of TIM-3 in leukemia will provide long-missing information for understanding the use of checkpoint inhibitors in treating liquid tumors. Overall, Dr. Sun\u2019s work may facilitate the development of new cancer therapeutic regimens.<\/p>\n\n\n\n
Role of TIM-3 in regulating anti-tumor immunity in AML<\/strong><\/p>\n\n\n\n Brigham & Women’s Hospital\/Harvard Medical School | Leukemia | 2023 | Vijay Kumar Kuchroo, PhD<\/p>\n","protected":false},"excerpt":{"rendered":" Checkpoint blockade immunotherapy has achieved durable responses in several solid tumor types by reinvigorating the anti-tumor function of T cells. However, many patients have shown limited responses and successful checkpoint blockade in […]<\/p>\n","protected":false},"featured_media":27954,"template":"","tax_cancer_type":[358],"tax_grant_type":[486],"tax_award_year":[480],"tax_institutions":[617],"tax_location_states":[],"class_list":["post-27391","cri_scientists","type-cri_scientists","status-publish","has-post-thumbnail","hentry"],"acf":{"scientist_subhead":"Postdoctoral Fellow","quote":"","scientist_last_name":"Sun","show_on_landing":true,"scientist_publish_until":"20260101"},"yoast_head":"\n